# RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients

> **NCT02257177** · PHASE1,PHASE2 · COMPLETED · sponsor: **Galecto Biotech AB** · enrollment: 60 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Inhaled TD139
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02257177
- **Lead sponsor:** Galecto Biotech AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02257177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02257177, "RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02257177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*